GlassScriptPhysician profile
Allison Kamm
NPI 1225511819
$1,624.18
in general payments reported to CMS, 2019-2025
24 companies · $650 in 2025
The $650 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $974 · 2025: $650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,624.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $292.79 | 2024-2025 | Airsupra |
| Pfizer INC. | $152.39 | 2024 | |
| Novo Nordisk INC | $152.32 | 2024-2025 | Wegovy |
| Glaxosmithkline, LLC. | $117.49 | 2024-2025 | Shingrix, Arexvy |
| Gilead Sciences, INC. | $113.01 | 2024-2025 | |
| Abbvie INC. | $112.05 | 2024-2025 | |
| Hologic Sales and Service, LLC | $99.30 | 2024-2025 | Aptima, Thinprep 2000 Processor |
| Astellas Pharma US INC | $77.27 | 2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $60.34 | 2025 | |
| Amgen INC. | $60.09 | 2024-2025 | Otezla, Repatha, Otezla |
| Exact Sciences Corporation | $56.77 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $50.89 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Lilly USA, LLC | $47.73 | 2024 | Mounjaro, Zepbound |
| Inogen, INC. | $33.50 | 2024 | |
| Dexcom, INC. | $31.47 | 2025 | Dexcom G6 Transmitter |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.84 | 2024 | Caplyta |
| Edwards Lifesciences Corporation | $25.57 | 2024 | Sapien 3 Ultra Resilia |
| Organon LLC | $21.79 | 2025 | Nexplanon |
| Abiomed | $17.86 | 2024 | Impella |
| Sumitomo Pharma America, INC. | $16.15 | 2024 | Gemtesa |
| C. R. Bard, INC. & Subsidiaries | $16.00 | 2024 | Bd Onclarity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.99 | 2024 | Xifaxan, Trulance |
| Idorsia Pharmaceuticals US INC | $14.02 | 2024 | Quviviq |
| Viiv Healthcare Company | $13.55 | 2024 | Apretude |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Kamm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.